- Ampliphi Biosciences (OTCQB:APHB +11.4%) restates its financial statements for the quarters ended September 30, 2013, December 31, 2013 and March 31, 2014 and for the year ended December 31, 3013 due to non-cash adjustments related to its Series B Preferred Stock dividend clause to reflect its treatment as a compound derivative.
- It will restate its financials for the year ended December 31, 2013 due to a reclassification of in-process R&D related to its acquisition of Biocontrol Ltd.
- The financials for the years ended December 31, 2011, 2012 and 2013 will be revised to recognize amortization of certain patents.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs